CXCL1 and systemic sclerosis: From the above, it is suggested that the deletion of B cells reduces IL-6 that is produced and induced by B cells, resulting in a decrease in CXCL1, which is one of the reasons for the improvement in lung function and skin sclerosis after B-cell-depletion therapy with anti-CD20 monoclonal antibodies in SSc patients.